Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 21-Nov-22 4:30 PM View:  | Kannan Raj Chief Executive Officer Director | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 215,783 | $15.25 | $3,290,690.00 | (100%) 215.78K to 0 | |
| 21-Nov-22 4:59 PM View: | McHugh Julie Director | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 16,095 | $15.25 | $245,449.00 | (100%) 16.09K to 0 | |
| 21-Nov-22 4:43 PM View: | Gryska David W Director | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 1,996 | $15.25 | $30,439.00 | (100%) 2.0K to 0 | |
| 21-Nov-22 4:54 PM View: | Kopczynski Casey C. Chief Scientific Officer | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 280,244 | $15.25 | $4,273,720.00 | (100%) 280.24K to 0 | |
| 21-Nov-22 4:41 PM View: | Du Toit Michael Director | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 16,095 | $15.25 | $245,449.00 | (100%) 16.09K to 0 | |
| 21-Nov-22 4:34 PM View: | Calabrese Jeffrey Vice President of Finance | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 18,585 | $15.25 | $283,421.00 | (100%) 18.59K to 0 | |
| 21-Nov-22 4:57 PM View: | McGraw Benjamin F III Director | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 41,984 | $15.25 | $640,256.00 | (100%) 41.98K to 0 | |
| 21-Nov-22 4:47 PM View: | Larocca John General Counsel | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 53,585 | $15.25 | $817,171.00 | (100%) 53.59K to 0 | |
| 21-Nov-22 4:37 PM View: | Croarkin Richard Director | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 16,095 | $15.25 | $245,449.00 | (100%) 16.09K to 0 | |
| 21-Nov-22 4:56 PM View: | McDonnell Peter J Director | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 7,995 | $15.25 | $121,924.00 | (100%) 8.0K to 0 | |
| 21-Nov-22 4:52 PM View: | Lang Peter Frederick Chief Financial Officer | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 46,297 | $15.25 | $706,029.00 | (100%) 46.3K to 0 | |
| 21-Nov-22 4:43 PM View: | Gryska David W Director | Aerie Pharmaceuticals, Inc. (AERI) | 21-Nov-22 | Disposition | 11,495 | $15.25 | $175,299.00 | (85%) 13.49K to 2.0K | |
| 03-Nov-22 7:41 PM View: | Calabrese Jeffrey Vice President of Finance | Aerie Pharmaceuticals, Inc. (AERI) | 01-Nov-22 | Payment of Exercise | 179 | $15.22 | $2,724.38 | (< 1%) 18.76K to 18.59K | |
| 16-Aug-22 4:14 PM View: | Calabrese Jeffrey Vice President of Finance | Aerie Pharmaceuticals, Inc. (AERI) | 14-Aug-22 | Payment of Exercise | 265 | $11.57 | $3,066.05 | (1%) 19.03K to 18.76K | |
| 16-Aug-22 4:16 PM View: | Larocca John General Counsel | Aerie Pharmaceuticals, Inc. (AERI) | 14-Aug-22 | Payment of Exercise | 771 | $11.57 | $8,920.47 | (1%) 54.36K to 53.59K | |
| 06-Jul-22 4:44 PM View: | Calabrese Jeffrey Vice President of Finance | Aerie Pharmaceuticals, Inc. (AERI) | 01-Jul-22 | Grant | 11,276 | -- | -- | 141% 8.02K to 19.3K | |
| 13-Jul-22 4:16 PM View: | Calabrese Jeffrey Vice President of Finance | Aerie Pharmaceuticals, Inc. (AERI) | 01-Jul-22 | Payment of Exercise | 266 | $8.36 | $2,223.76 | (1%) 19.3K to 19.03K | 2% |
| 13-Jun-22 5:10 PM View: | Du Toit Michael Director | Aerie Pharmaceuticals, Inc. (AERI) | 09-Jun-22 | Grant | 6,245 | -- | -- | 63% 9.85K to 16.09K | |
| 13-Jun-22 5:18 PM View: | McGraw Benjamin F III Director | Aerie Pharmaceuticals, Inc. (AERI) | 09-Jun-22 | Grant | 6,245 | -- | -- | 17% 35.74K to 41.98K | |
| 13-Jun-22 4:43 PM View: | Croarkin Richard Director | Aerie Pharmaceuticals, Inc. (AERI) | 09-Jun-22 | Grant | 6,245 | -- | -- | 63% 9.85K to 16.09K | |
| 13-Jun-22 5:16 PM View: | McDonnell Peter J Director | Aerie Pharmaceuticals, Inc. (AERI) | 09-Jun-22 | Grant | 6,245 | -- | -- | 357% 1.75K to 8.0K | |
| 13-Jun-22 5:13 PM View: | Gryska David W Director | Aerie Pharmaceuticals, Inc. (AERI) | 09-Jun-22 | Grant | 6,245 | -- | -- | 86% 7.25K to 13.49K | |
| 13-Jun-22 5:21 PM View: | McHugh Julie Director | Aerie Pharmaceuticals, Inc. (AERI) | 09-Jun-22 | Grant | 6,245 | -- | -- | 63% 9.85K to 16.09K | |
| 22-Mar-22 8:29 PM View: | Larocca John General Counsel | Aerie Pharmaceuticals, Inc. (AERI) | 18-Mar-22 | Grant | 19,015 | -- | -- | 54% 35.34K to 54.36K | |
| 22-Mar-22 8:21 PM View: | Lang Peter Frederick Chief Financial Officer | Aerie Pharmaceuticals, Inc. (AERI) | 18-Mar-22 | Grant | 46,297 | -- | -- | 100% 0 to 46.3K | |
| 22-Mar-22 8:32 PM View: | Kopczynski Casey C. Chief Scientific Officer | Aerie Pharmaceuticals, Inc. (AERI) | 18-Mar-22 | Grant | 19,015 | -- | -- | 7% 261.23K to 280.24K | |
| 02-Mar-22 5:38 PM View: | McGraw Benjamin F III Interim Executive Chair Director | Aerie Pharmaceuticals, Inc. (AERI) | 28-Feb-22 | Payment of Exercise | 10,324 | $8.30 | $85,689.20 | (22%) 46.06K to 35.74K | < 1% |
| 23-Feb-22 4:41 PM View: | Larocca John General Counsel | Aerie Pharmaceuticals, Inc. (AERI) | 19-Feb-22 | Payment of Exercise | 1,973 | $6.00 | $11,838.00 | (5%) 37.31K to 35.34K | |
| 09-Feb-22 7:41 PM View: | Mitro Thomas A President and COO | Aerie Pharmaceuticals, Inc. (AERI) | 08-Feb-22 | Payment of Exercise | 1,111 | $7.33 | $8,143.63 | (1%) 82.53K to 81.42K | (12%) |
| 09-Feb-22 7:44 PM View: | Kopczynski Casey C. Chief Scientific Officer | Aerie Pharmaceuticals, Inc. (AERI) | 08-Feb-22 | Payment of Exercise | 700 | $7.33 | $5,131.00 | (< 1%) 261.93K to 261.23K | (12%) |
| 09-Feb-22 7:44 PM View: | Kopczynski Casey C. Chief Scientific Officer | Aerie Pharmaceuticals, Inc. (AERI) | 07-Feb-22 | Payment of Exercise | 701 | $7.24 | $5,075.24 | (< 1%) 262.63K to 261.93K | (14%) |
| 09-Feb-22 7:42 PM View: | Larocca John General Counsel | Aerie Pharmaceuticals, Inc. (AERI) | 07-Feb-22 | Payment of Exercise | 768 | $7.24 | $5,560.32 | (2%) 38.08K to 37.31K | (14%) |
| 09-Feb-22 7:41 PM View: | Mitro Thomas A President and COO | Aerie Pharmaceuticals, Inc. (AERI) | 07-Feb-22 | Payment of Exercise | 1,310 | $7.24 | $9,484.40 | (2%) 83.84K to 82.53K | (14%) |
| 08-Feb-22 8:39 PM View: | Kopczynski Casey C. Chief Scientific Officer | Aerie Pharmaceuticals, Inc. (AERI) | 06-Feb-22 | Payment of Exercise | 876 | $7.05 | $6,175.80 | (< 1%) 263.51K to 262.63K | (17%) |
| 08-Feb-22 8:38 PM View: | Larocca John General Counsel | Aerie Pharmaceuticals, Inc. (AERI) | 06-Feb-22 | Payment of Exercise | 384 | $7.05 | $2,707.20 | (< 1%) 38.47K to 38.08K | (17%) |
| 08-Feb-22 8:36 PM View: | Mitro Thomas A President and COO | Aerie Pharmaceuticals, Inc. (AERI) | 06-Feb-22 | Payment of Exercise | 1,435 | $7.05 | $10,116.80 | (2%) 85.27K to 83.84K | (17%) |
| 08-Feb-22 8:38 PM View: | Larocca John General Counsel | Aerie Pharmaceuticals, Inc. (AERI) | 04-Feb-22 | Payment of Exercise | 1,206 | $7.05 | $8,502.30 | (3%) 39.67K to 38.47K | (17%) |
| 08-Feb-22 8:36 PM View: | Mitro Thomas A President and COO | Aerie Pharmaceuticals, Inc. (AERI) | 04-Feb-22 | Payment of Exercise | 1,435 | $7.05 | $10,116.80 | (2%) 86.71K to 85.27K | (17%) |
| 08-Feb-22 8:40 PM View: | Hollander David Chief R&D Officer | Aerie Pharmaceuticals, Inc. (AERI) | 04-Feb-22 | Payment of Exercise | 927 | $7.05 | $6,535.35 | (3%) 31.68K to 30.75K | (17%) |
| 08-Feb-22 8:39 PM View: | Kopczynski Casey C. Chief Scientific Officer | Aerie Pharmaceuticals, Inc. (AERI) | 04-Feb-22 | Payment of Exercise | 963 | $7.05 | $6,789.15 | (< 1%) 264.47K to 263.51K | (17%) |
| 01-Feb-22 5:08 PM View: | McGinley Kathleen CHRO & VP, Corp Services | Aerie Pharmaceuticals, Inc. (AERI) | 30-Jan-22 | Payment of Exercise | 878 | $6.92 | $6,075.76 | (4%) 24.87K to 23.99K | (19%) |
| 22-Dec-21 8:07 PM View: | Kannan Raj Chief Executive Officer Director | Aerie Pharmaceuticals, Inc. (AERI) | 20-Dec-21 | Grant | 215,783 | -- | -- | 100% 0 to 215.78K | |
| 15-Nov-21 4:44 PM View: | Hollander David Chief R&D Officer | Aerie Pharmaceuticals, Inc. (AERI) | 11-Nov-21 | Payment of Exercise | 2,162 | $12.06 | $26,073.70 | (6%) 33.84K to 31.68K | 2% |
| 22-Sep-21 10:00 PM View: | McGraw Benjamin F III Interim Executive Chair Director | Aerie Pharmaceuticals, Inc. (AERI) | 20-Sep-21 | Grant | 34,513 | -- | -- | 299% 11.55K to 46.06K | |
| 17-Aug-21 10:00 PM View: | Larocca John General Counsel | Aerie Pharmaceuticals, Inc. (AERI) | 14-Aug-21 | Payment of Exercise | 765 | $14.70 | $11,245.50 | (2%) 40.44K to 39.67K | < 1% |
| 21-Jun-21 4:39 PM View: | Gryska David W Director | Aerie Pharmaceuticals, Inc. (AERI) | 17-Jun-21 | Grant | 1,750 | -- | -- | 32% 5.5K to 7.25K | |
| 21-Jun-21 4:21 PM View: | McHugh Julie Director | Aerie Pharmaceuticals, Inc. (AERI) | 17-Jun-21 | Grant | 1,750 | -- | -- | 22% 8.1K to 9.85K | |
| 21-Jun-21 4:36 PM View: | McGraw Benjamin F III Director | Aerie Pharmaceuticals, Inc. (AERI) | 17-Jun-21 | Grant | 1,750 | -- | -- | 18% 9.8K to 11.55K | |
| 21-Jun-21 4:18 PM View: | Du Toit Michael Director | Aerie Pharmaceuticals, Inc. (AERI) | 17-Jun-21 | Grant | 1,750 | -- | -- | 22% 8.1K to 9.85K | |
| 21-Jun-21 4:15 PM View: | Cagle Gerald D. Director | Aerie Pharmaceuticals, Inc. (AERI) | 17-Jun-21 | Grant | 1,750 | -- | -- | 10% 18.3K to 20.05K |
